Zimmer Biomet (ZBH) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $2.07
- EPS estimate
- $2.01
- EPS surprise
- +2.97%
- Revenue surprise
- +1.97%
- Revenue
- $2.2B
- Revenue estimate
- $2.1B
- Reported
- Aug 5, 2026
Zimmer Biomet reported Q2 2026 results on August 5, 2026. Earnings per share were $2.07, ahead of the $2.01 estimate by 2.97%. Revenue was about $2.2 billion, above the $2.1 billion consensus and the highest quarter in the table. EPS was unchanged from Q2 2025's $2.07, while revenue rose from $2.1 billion.
The longer record shows steady but slowing growth. Annual EPS rose from $6.89 in 2022 to $7.56 in 2023, $8.00 in 2024 and $8.20 in 2025. The 2025 gain was about 2.5%. The first half of 2026 adds up to $4.16, about 7% more than the first half of 2025. Q4 was the strongest quarter in every full year shown, and Q4 2025 set the table's EPS high at $2.42. Zimmer Biomet beat the EPS estimate in 18 of the last 20 quarters. The two misses, in Q4 2021 and Q3 2024, were each within about 1.3% of the estimate.
Zimmer Biomet reported Q3 results between October 30 and November 7 in each of the last five years. That points to late October or early November 2026 for the next report. It will show whether the first-half gain over 2025 holds up in Q3.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 5, 2026 | $2.01 | $2.07 | +2.97% | $2.2B | SEC |
| Q1 2026 | Apr 28, 2026 | $1.87 | $2.09 | +12.05% | $2.1B | SEC |
| Q4 2025 | Feb 10, 2026 | $2.40 | $2.42 | +0.92% | $2.2B | SEC |
| Q3 2025 | Nov 5, 2025 | $1.87 | $1.90 | +1.82% | $2.0B | SEC |
| Q2 2025 | Aug 7, 2025 | $1.98 | $2.07 | +4.61% | $2.1B | SEC |
| Q1 2025 | May 5, 2025 | $1.77 | $1.81 | +2.22% | $1.9B | SEC |
| Q4 2024 | Feb 6, 2025 | $2.30 | $2.31 | +0.64% | $2.0B | SEC |
| Q3 2024 | Oct 30, 2024 | $1.74 | $1.74 | −0.22% | $1.8B | SEC |
| Q2 2024 | Aug 7, 2024 | $1.99 | $2.01 | +0.95% | $1.9B | SEC |
| Q1 2024 | May 2, 2024 | $1.87 | $1.94 | +3.72% | $1.9B | SEC |
| Q4 2023 | Feb 8, 2024 | $2.15 | $2.20 | +2.15% | $1.9B | SEC |
| Q3 2023 | Nov 7, 2023 | $1.60 | $1.65 | +3.27% | $1.8B | SEC |
| Q2 2023 | Aug 1, 2023 | $1.82 | $1.82 | +0.11% | $1.9B | SEC |
| Q1 2023 | May 2, 2023 | $1.64 | $1.89 | +15.34% | $1.8B | SEC |
| Q4 2022 | Feb 3, 2023 | $1.83 | $1.88 | +2.87% | $1.8B | SEC |
| Q3 2022 | Nov 2, 2022 | $1.55 | $1.58 | +1.66% | $1.7B | SEC |
| Q2 2022 | Aug 2, 2022 | $1.64 | $1.82 | +10.91% | $1.8B | SEC |
| Q1 2022 | Apr 28, 2022 | $1.40 | $1.61 | +14.81% | $1.7B | SEC |
| Q4 2021 | Feb 7, 2022 | $1.92 | $1.89 | −1.32% | $2.0B | SEC |
| Q3 2021 | Nov 4, 2021 | $1.70 | $1.76 | +3.06% | $1.9B | SEC |
Quarterly revenue
Frequently asked questions
When did Zimmer Biomet (ZBH) last report earnings?
Zimmer Biomet last reported on Aug 5, 2026, covering fiscal Q2 2026.
Did ZBH beat earnings estimates?
Yes. Zimmer Biomet reported EPS of $2.07 for Q2 2026 against a $2.01 estimate — a 2.97% beat.
How much revenue did ZBH report last quarter?
Zimmer Biomet reported $2.2B in revenue for Q2 2026, against a consensus estimate of $2.1B.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.